HC Wainwright Issues Positive Forecast for Evommune Earnings

Evommune, Inc. (NYSE:EVMN – Free Report) – Stock analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Evommune in a research note issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($3.28) per share for the year, up from their previous estimate of ($3.41). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Evommune’s current full-year earnings is ($3.37) per share. HC Wainwright also issued estimates for Evommune’s Q4 2026 earnings at ($0.88) EPS, Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.83) EPS, Q3 2027 earnings at ($0.86) EPS, Q4 2027 earnings at ($0.91) EPS and FY2027 earnings at ($3.45) EPS.

Evommune (NYSE:EVMN – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.03).

A number of other research firms also recently weighed in on EVMN. Weiss Ratings downgraded shares of Evommune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 11th. Wall Street Zen lowered shares of Evommune from a “sell” rating to a “strong sell” rating in a report on Saturday, November 14th. Leerink Partners dropped their price target on shares of Evommune from $28.00 to $22.00 and set an “outperform” rating on the stock in a research report on Wednesday, September 9th. Needham & Company LLC reduced their price objective on shares of Evommune from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, November 13th. Finally, Stifel Nicolaus set a $30.00 price objective on shares of Evommune in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $30.50.

Read Our Latest Analysis on Evommune

Evommune Stock Down 1.8%

Evommune stock opened at $6.89 on Tuesday. The stock’s 50 day moving average is $7.25 and its 200 day moving average is $16.91. Evommune has a one year low of $4.94 and a one year high of $33.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC bought a new stake in shares of Evommune during the 1st quarter valued at about $20,615,000. Defilade Capital Management L.P. grew its stake in Evommune by 215.0% during the first quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock worth $15,601,000 after purchasing an additional 463,171 shares during the period. Perceptive Advisors LLC acquired a new stake in Evommune during the first quarter worth approximately $10,308,000. Baker BROS. Advisors LP increased its holdings in Evommune by 45.7% in the third quarter. Baker BROS. Advisors LP now owns 1,234,794 shares of the company’s stock worth $10,199,000 after purchasing an additional 387,404 shares in the last quarter. Finally, Velan Capital Investment Management LP increased its holdings in Evommune by 1.1% in the second quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company’s stock worth $5,997,000 after purchasing an additional 5,000 shares in the last quarter.

Evommune Company Profile

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Founded in 2020, the company focuses on biological pathways involved in inflammation and aims to develop treatments for conditions with significant unmet medical needs. Its pipeline includes EVO756, an oral investigational medicine designed to block MRGPRX2, a receptor involved in mast-cell activation. The candidate is being studied for inflammatory skin disorders, including chronic spontaneous urticaria and atopic dermatitis.

Featured Articles

Earnings History and Estimates for Evommune (NYSE:EVMN)

Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.